Strategic Focus Hepregen is targeting the drug development and safety assessment space with its HepatoPac microliver platform, presenting a clear need for pharmaceutical and biotech customers seeking more predictive in vitro liver models to de-risk preclinical programs.

Trusted Partnerships With over 20 pharmaceutical company partners leveraging HepatoPac, there is a proven market traction and a network to reference in discussions, easing credibility in new business conversations.

Integration Readiness HepatoPac fits into existing workflows and supports high-content screening, making it an attractive add-on for teams aiming to enhance DMPK, safety screening, and efficacy assessment without disrupting current lab processes.

Scale and Capability The platform demonstrates sustained hepatocyte functionality (up to 4 weeks in vitro) and multi-environment liver biology, suggesting opportunities for expanded use cases such as disease modeling and stem cell applications to widen addressable markets.

Growth Signals With a lean team (2-10 employees) and early-stage revenue, Hepregen presents an opportunity for strategic investments or collaboration deals to accelerate scale, broaden indications, and capitalize on the growing demand for advanced in vitro liver models.